What is ICH M4?
ICH M4 is the guideline that defines the Common Technical Document. It is how FDA, EMA, Health Canada, and PMDA agreed on a single harmonized submission structure so sponsors stop re-formatting content per region. Four sub-guidelines fill in the details: M4 for organization, M4Q for Quality, M4S for Safety, M4E for Efficacy.
Short answer. ICH M4 is the International Council for Harmonisation guideline defining CTD organization. M4Q governs Module 3 Quality content, M4S governs Module 4 Safety, M4E governs Module 5 Efficacy. Current versions: M4(R4), M4Q(R2) 2025 revision, M4S(R2), M4E(R2).
The four sub-guidelines
- M4 — Organization of the CTD. Defines what goes in Modules 2-5 at a structural level. Module 1 is out of scope (region-specific).
- M4Q — Quality. Specifies the content of Module 3 (3.2.S drug substance, 3.2.P drug product, 3.2.A appendices, 3.2.R regional) and Module 2.3 (Quality Overall Summary). Current version M4Q(R2), 2025 revision.
- M4S — Safety. Specifies Module 4 (nonclinical study reports: pharmacology, pharmacokinetics, toxicology) and Module 2.4 / 2.6 (Nonclinical Overview, Nonclinical Summary). Current version M4S(R2).
- M4E — Efficacy. Specifies Module 5 (clinical study reports) and Module 2.5 / 2.7 (Clinical Overview, Clinical Summary). Current version M4E(R2).
What M4 does not cover
- Module 1. Administrative content is region-specific. FDA Module 1 looks different from EMA's, which differs from Health Canada's Module 1. Each region publishes its own Module 1 specification.
- eCTD packaging. ICH M8 covers the electronic format; M4 only covers content structure.
- GMP or inspection requirements. Those live in ICH Q7 (API GMP) and the regional GMP regulations (21 CFR 210/211 in US, EU GMP Part I, Health Canada Division 2).
Related guidelines
M4 sits alongside the ICH Q-series (Quality), E-series (Efficacy), S-series (Safety), and M-series (Multidisciplinary):
- Quality: Q1 (stability), Q2 (method validation), Q3 (impurities), Q5 (biotech), Q6 (specifications), Q7 (API GMP), Q8 (pharmaceutical development), Q9 (risk), Q10 (PQS), Q11 (drug substance), Q12 (lifecycle), Q13 (continuous manufacturing).
- Efficacy: E6 (GCP), E8 (general considerations for clinical studies), E9 (statistical principles), E17 (multi-regional clinical trials).
- Safety: S1-S10 covering carcinogenicity, genotoxicity, reproductive toxicity, etc.
- Multidisciplinary: M1 (MedDRA), M3 (nonclinical for clinical), M7 (mutagenic impurities), M8 (eCTD), M9 (biowaivers).
Related glossary entries
Frequently asked questions
What is ICH M4?
ICH M4 is the guideline defining the organization of the Common Technical Document (CTD). It specifies the structure of Modules 2-5 and provides the framework all ICH-participating agencies use for marketing authorization.
What is the difference between M4, M4Q, M4S, M4E?
M4 covers overall CTD organization. M4Q covers Quality (Module 3). M4S covers Safety (Module 4, nonclinical). M4E covers Efficacy (Module 5, clinical).
Which versions are currently in force?
M4(R4) for the framework, M4Q(R2) 2025 revision for Quality, M4S(R2) for Safety, M4E(R2) for Efficacy. Regional implementation timing can vary 6-12 months between ICH regions.
Does ICH M4 apply to generics?
Yes. ANDA (US, 21 CFR 314.94), ANDS (Canada, Food and Drug Regulations C.08.002.1), and EMA's generic procedure all use the CTD format with Module 3 CMC authored to M4Q.